Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Use of Cardiac MRI in Early Stages of STEMI to Predict Left Ventricular Function Recovery and ICD Implantation (STEMI-MR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03743935
Recruitment Status : Recruiting
First Posted : November 16, 2018
Last Update Posted : May 15, 2019
Sponsor:
Collaborator:
Société Française de Cardiologie
Information provided by (Responsible Party):
University Hospital, Montpellier

Brief Summary:

Patients presenting with STEMI and late revascularization can suffer from severe left ventricular dysfunction. Midterm and longterm mortality can be determined by the risk of fatal ventricular arrythmias. For this specific population, ESC guidelines currently recommend a waiting period of up to 40 days after a STEMI with severe left ventricular dysfunction before considering ICD implantation for primary prevention of sudden death.This delay is allocated to judge left ventricular recovery.

This study aims to see whether early cardiac MRI with specific sequences can help predict which patients will most probably not recover their left ventricular function and benefit from earlier ICD implantation.


Condition or disease Intervention/treatment Phase
Acute STEMI Severe Left Ventricular Systolic Dysfunction (Disorder) Other: Gadolinium-enhanced cardiac MRI Not Applicable

Detailed Description:

ST segment elevation myocardial infarction represent 120 000 annual cases in France. Although its mortality has been drastically reduced by primary percutaneous coronary angioplasty (PCI), its midterm and longterm outcome in patients presenting initially with severe left ventricular (LV) dysfunction depends on the risks of heart failure and sudden death by malignant ventricular arrhythmias.

Many clinical studies such as MADIT I and II, MUSTT and DINAMIT have participated in defining which patients should benefit from ICD implantation. These studies were based on evaluation of the LV ejection fraction (LVEF) and of the risk of arrhythmia (by electrophysiology or holter recordings).

However, ESC Guidelines recommend a mandatory waiting period of 40 days post-PCI to reevaluate LVEF before confirming the need for ICD implantation (LVEF < 35%). Therefore, patients are at risk of sudden cardiac death (SCD). during this period.

The investigators sought to determine whether specific cardiac MRI sequences could help predict which patients would eventually recover from their LV dysfunction and therefore reduce the risk of SCD by implanting ICD earlier than recommended.

Patients presenting at our Cardiac ICU with STEMI and severe LV dysfunction (LVEF < 35%), not indicated to coronary artery bypass surgery (CABG) and free from initial cardiac arrest or severe ventricular arrhythmias, will be included. They will undergo a gadolinium-enhanced cardiac MRI during the 1st days of hospitalization with specific sequences to determine myocardial zones at risk of non-recovery.

Initial assessment will also include thorough clinical examination with NYHA class, trans-thoracic echocardiography and blood works to evaluate renal function, inflammation, signs of heart failyre (BNP and troponin). Patients will be equipped with Lifevests for 6 weeks and followed-up with the same criteria.

Ratio of final ICD implantation will then be compared to the MRI criterion to determine whether LV recovery could have been predicted.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Primary Prevention ICD Implantation in STEMI With Severe Left Ventricular Dysfunction : Input of Early Cardiac MRI in Order to Predict Left Ventricular Recovery
Actual Study Start Date : January 7, 2019
Estimated Primary Completion Date : May 1, 2020
Estimated Study Completion Date : August 1, 2020

Arm Intervention/treatment
Experimental: Early cardiac MRI post-STEMI
Early stages post-STEMI (within the first 5 days)
Other: Gadolinium-enhanced cardiac MRI
Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement




Primary Outcome Measures :
  1. Mesure of zones of delayed myocardial transmural enhancement and no-reflow [ Time Frame: 40 days ]
    Defining the area at risk with Cardiac MRI

  2. Mesure of ejection fraction and regional wall motion and thickening [ Time Frame: 40 days ]
    Defining the area at risk with Cardiac MRI

  3. Mesure of extracellular volume [ Time Frame: 40 days ]
    Defining the area at risk with Cardiac MRI


Secondary Outcome Measures :
  1. Number of CVD events [ Time Frame: 40 days ]
    Occurrence of major adverse cardiac events

  2. Number of admission to the hospital for heart failure event [ Time Frame: 40 days ]
    Occurrence of heart failure events

  3. Number of ischemic cardiovascular events [ Time Frame: 40 days ]
    Occurrence of major adverse cardiac events

  4. Number of cardiac death [ Time Frame: 40 days ]
    Occurrence of major adverse cardiac events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Acute STEMI within 5 last days with LVEF < 35%
  • 18-80 years old
  • Admitted to the Cardiac ICU
  • Consent form

Exclusion Criteria:

  • CABG surgery indicated
  • Contra-indications to MRI
  • ICD or PPM in place
  • Follow-up compromised

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03743935


Contacts
Layout table for location contacts
Contact: Jean-Luc PASQUIE, MD-PhD 0467336187 ext 33 jl-pasquie@chu-montpellier.fr
Contact: Julie Roux, MD juliejm.roux@gmail.com

Locations
Layout table for location information
France
University Hospital of Montpellier Recruiting
Montpellier, France, 34090
Contact: Sonia Soltani, Engineer       s-soltani@chu-montpellier.fr   
Sponsors and Collaborators
University Hospital, Montpellier
Société Française de Cardiologie
Publications:
Layout table for additonal information
Responsible Party: University Hospital, Montpellier
ClinicalTrials.gov Identifier: NCT03743935    
Other Study ID Numbers: UF 7649
First Posted: November 16, 2018    Key Record Dates
Last Update Posted: May 15, 2019
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Montpellier:
STEMI
MRI
ICD
Sudden death
Additional relevant MeSH terms:
Layout table for MeSH terms
ST Elevation Myocardial Infarction
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases